ANEB Anebulo Pharma: Forward P/S Multiple

Brandmark of Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals focuses on a narrow segment of THC antidotes, which creates a dependency on regulators. The company's forward P/S valuation provided by the GURU.Markets platform demonstrates current dynamics, where determines this parameter level. The absence of peers guarantees stable income, while the unique drug ANI-4003 ensures absolute pricing power due to inelastic demand.

ANEB (Anebulo Pharmaceuticals, Inc.) Forward P/S Multiple history from 07/04/2022 to 11/16/2026

ANEB (Anebulo Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Summary company analysis:ANEB (Anebulo Pharmaceuticals, Inc.)
Original product of anebulo.com

The forward P/S reflects the ratio of the current market value of Anebulo Pharmaceuticals (ANEB) to its projected revenue for the coming year, allowing investors to assess the premium paid for future growth. Since the lack of FDA-approved drugs deprives the company of pricing power, the future P/S multiple becomes a key indicator of speculative expectations regarding clinical trial outcomes and future patent protection for the business.